Abstract:Tumor‐targeting bacteria have been developed as powerful anticancer agents. Salmonella typhimurium VNP20009, a representative tumor‐targeting strain, has been systemically administered as a single‐agent therapy at doses of 1 × 106 to 3 × 106 colony‐forming unit (cfu)/mouse, or in combination with other antitumor agents at doses of 1 × 104 to 2 × 105 cfu/mouse. Recently, we reported that oral delivery of VNP20009 at the dose of 1 × 109 cfu/mouse induced significant anticancer effects comparable to that induced by systemic administration of this strain at 1 × 104 cfu/mouse. To further address the efficacy and safety of oral administration of bacteria, here we performed a systemically comparative analysis of anticancer efficacy and toxicity of VNP20009 administered: (i) orally at a dose of 1 × 109 cfu/mouse (VNP9‐oral); (ii) intraperitoneally at a dose of 1 × 104 cfu/mouse (VNP4‐i.p.); or (iii) intraperitoneally at a dose of 1 × 106 cfu/mouse in tumor‐free and tumor‐bearing murine models. The results showed that VNP9‐oral, similar to VNP4‐i.p., induced significant tumor growth inhibition whereas VNP6‐i.p. induced better anticancer effect in the B16F10 melanoma model. Among three treatments, VNP9‐oral induced the mildest and reversible toxicity whereas VNP6‐i.p. resulted in the most serious and irreversible toxicities when compared to other two treatments. Moreover, the combination of VNP9‐oral with a low dose of chemotherapeutics produced comparable antitumor effects but displayed significantly reduced toxicity when compared to VNP6‐i.p. The findings demonstrated that oral administration, as a novel avenue in the application of bacteria, is highly safe and effective. Moreover, the present preclinical study should facilitate the optimization of bacterial therapies with improved anticancer efficacy and reduced adverse effects in future clinical trials. (Cancer Sci 2009; 100: 2437–2443)

Attenuated Salmonella Typhimurium Carrying TRAIL and VP3 Genes Inhibits the Growth of Gastric Cancer Cells in Vitro and in Vivo

Targeted Expression of Green Fluorescent Protein/Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand Fusion Protein from Human Telomerase Reverse Transcriptase Promoter Elicits Antitumor Activity Without Toxic Effects on Primary Human Hepatocytes

Long-term tumor-free survival from treatment with the GFP–TRAIL fusion gene expressed from the hTERT promoter in breast cancer cells

Anti-liver Cancer Activity of TNF-related Apoptosis-Inducing Ligand Gene and Its Bystander Effects.

Tumor necrosis factor-related apoptosis-inducing ligand gene on human colorectal cancer cell line HT29.

Lentivirus-mediated Gene Transfer of Human Strail Induced Apoptosis in SGC-7901 Cells

Treatment of patient tumor-derived colon cancer xenografts by a TRAIL gene-armed oncolytic adenovirus

[Activity of the TNF-related Apoptosis-Inducing Ligand Gene Expressed from the Htert Promoter on Colon Cancer Cell Line HT-29].

Salmonella-mediated tumor-targeting TRAIL gene therapy significantly suppresses melanoma growth in mouse model.

[Action of Apoptosis-Induced Ligand Gene in Relation to Tumor Necrosis Factor on Human Colon Cancer Cell Line HT29].

Synergistic antitumoral effects of human telomerase reverse transcriptase-mediated dual-apoptosis-related gene vector delivered by orally attenuated Salmonella enterica Serovar Typhimurium in murine tumor models.

Attenuated Salmonella typhimurium L forms suppress tumor growth and promote apoptosis in murine ovarian tumors

AttenuatedSalmonella VNP20009 Mutant(δhtra) is a Promising Candidate for Bacteria-Mediated Tumour Therapy in Hosts with TNFR1 Deficiency

Bacterial cancer therapy using the attenuated fowl-adapted Salmonella enterica serovar Gallinarum

sTRAIL-iRGD is a promising therapeutic agent for gastric cancer treatment

Salmonella-Mediated Cytolethal Distending Toxin Transfer Inhibits Tumor Growth

Esophageal cancer-selective expression of TRAIL mediated by MREs of miR-143 and miR-122

Oral Delivery of Tumor‐targeting Salmonella Exhibits Promising Therapeutic Efficacy and Low Toxicity

Functions Of The Ap-2 Alpha Gene In Activating Apoptosis And Inhibiting Proliferation Of Gastric Cancer Cells Both In Vitro And In Vivo

Suppression of pancreatic tumor growth in the liver by systemic administration of the TRAIL gene driven by the hTERT promoter

Two-step enhanced cancer immunotherapy with engineered Salmonella typhimurium secreting heterologous flagellin